FY2024 EPS Estimate for Alto Neuroscience Boosted by Analyst

Alto Neuroscience, Inc. (NYSE:ANRO) – William Blair lifted their FY2024 EPS estimates for shares of Alto Neuroscience in a report released on Wednesday, November 13th. William Blair analyst M. Minter now forecasts that the company will earn ($2.65) per share for the year, up from their previous forecast of ($2.73). William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Alto Neuroscience’s current full-year earnings is ($2.60) per share. William Blair also issued estimates for Alto Neuroscience’s Q4 2024 earnings at ($0.70) EPS, Q1 2025 earnings at ($0.59) EPS, Q2 2025 earnings at ($0.61) EPS, Q3 2025 earnings at ($0.62) EPS, Q4 2025 earnings at ($0.65) EPS, FY2025 earnings at ($2.47) EPS, FY2026 earnings at ($2.22) EPS, FY2027 earnings at ($2.21) EPS and FY2028 earnings at ($3.06) EPS.

Several other research firms have also commented on ANRO. Wedbush lowered shares of Alto Neuroscience from an “outperform” rating to a “neutral” rating and lowered their price objective for the company from $29.00 to $4.00 in a research report on Wednesday, October 23rd. Robert W. Baird lowered their price target on shares of Alto Neuroscience from $32.00 to $10.00 and set an “outperform” rating for the company in a report on Wednesday, October 23rd. Stifel Nicolaus reduced their price objective on Alto Neuroscience from $32.00 to $10.00 and set a “buy” rating on the stock in a research note on Wednesday, November 13th. Rodman & Renshaw downgraded Alto Neuroscience from a “buy” rating to a “neutral” rating in a research report on Wednesday, October 23rd. Finally, RODMAN&RENSHAW cut Alto Neuroscience from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 23rd. Three investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $20.00.

Alto Neuroscience Stock Up 2.0 %

NYSE ANRO opened at $4.61 on Monday. The stock has a 50 day moving average price of $9.69 and a 200-day moving average price of $11.27. Alto Neuroscience has a one year low of $3.61 and a one year high of $24.00. The company has a current ratio of 13.10, a quick ratio of 19.85 and a debt-to-equity ratio of 0.05.

Alto Neuroscience (NYSE:ANRO) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.62) EPS for the quarter, beating analysts’ consensus estimates of ($0.67) by $0.05.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of ANRO. Vanguard Group Inc. purchased a new stake in shares of Alto Neuroscience during the first quarter valued at $8,233,000. Price T Rowe Associates Inc. MD bought a new stake in Alto Neuroscience during the 1st quarter valued at about $9,788,000. Bowie Capital Management LLC purchased a new stake in Alto Neuroscience in the 2nd quarter valued at about $462,000. TD Asset Management Inc bought a new position in Alto Neuroscience in the 2nd quarter worth about $928,000. Finally, Zimmer Partners LP bought a new position in Alto Neuroscience in the 1st quarter worth about $1,151,000.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.